SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and…
REPOSE® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with Axoguard Nerve Cap®…
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming…
Board Will Serve as Strategic Advisors to Accelerate Research for Millions of Patients Living With Chronic, Multisystem DisordersSALT LAKE CITY,…
Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas…
Ashley Bates Transitions to Sr. Director Consulting & Partnerships at Just in Time GCPPHILADELPHIA, PA / ACCESSWIRE / January 18,…
Osteoboost is the first and only non-pharmacological prescription treatment to demonstrate reduced loss of bone strength in postmenopausal womenRepresents the…
Secures Two Research Grants from Belgium's New Technological Innovation PartnershipLONDON, UK / ACCESSWIRE / January 18, 2024 / The Company…
Cannabix Technologies Inc. Fig. 1 Cannabix at North Louisiana Crime Lab Cannabix Technologies Inc. Fig. 2 Cannabix MSBS at North…
A post hoc analysis found the efficacy of camrelizumab plus rivoceranib was superior to sorafenib regardless of baseline liver function…